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http://www.biomedcentral.com/1741-7015/12/58RESEARCH ARTICLE Open AccessFormal and informal prediction of recurrent
stroke and myocardial infarction after stroke:
a systematic review and evaluation of clinical
prediction models in a new cohort
Douglas D Thompson1*, Gordon D Murray1, Martin Dennis2, Cathie LM Sudlow2 and William N Whiteley1,2Abstract
Background: The objective of this study was to: (1) systematically review the reporting and methods used in the
development of clinical prediction models for recurrent stroke or myocardial infarction (MI) after ischemic stroke; (2)
to meta-analyze their external performance; and (3) to compare clinical prediction models to informal clinicians’
prediction in the Edinburgh Stroke Study (ESS).
Methods: We searched Medline, EMBASE, reference lists and forward citations of relevant articles from 1980 to 19
April 2013. We included articles which developed multivariable clinical prediction models for the prediction of
recurrent stroke and/or MI following ischemic stroke. We extracted information to assess aspects of model
development as well as metrics of performance to determine predictive ability. Model quality was assessed against
a pre-defined set of criteria. We used random-effects meta-analysis to pool performance metrics.
Results: We identified twelve model development studies and eleven evaluation studies. Investigators often did
not report effective sample size, regression coefficients, handling of missing data; typically categorized continuous
predictors; and used data dependent methods to build models. A meta-analysis of the area under the receiver
operating characteristic curve (AUROCC) was possible for the Essen Stroke Risk Score (ESRS) and for the Stroke
Prognosis Instrument II (SPI-II); the pooled AUROCCs were 0.60 (95% CI 0.59 to 0.62) and 0.62 (95% CI 0.60 to 0.64),
respectively. An evaluation among minor stroke patients in the ESS demonstrated that clinicians discriminated poorly
between those with and those without recurrent events and that this was similar to clinical prediction models.
Conclusions: The available models for recurrent stroke discriminate poorly between patients with and without a
recurrent stroke or MI after stroke. Models had a similar discrimination to informal clinicians' predictions. Formal
prediction may be improved by addressing commonly encountered methodological problems.
Keywords: Systematic review, Meta-analysis, Stroke, Prediction, Statistical modelling, Evaluation, DevelopmentBackground
About a quarter of the patients who survive their stroke
have a recurrent stroke within five years [1]. Any method
that could reliably discriminate between those patients at
high risk and those at low risk of recurrent stroke would
be useful. Patients and their clinicians might use such* Correspondence: D.Thompson-3@sms.ed.ac.uk
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article, unless otherwise stated.information to make decisions about different preventive
strategies and better target resources.
Clinical prediction models (also known as prognostic/
statistical models or scores) combine multiple risk factors
to estimate the absolute risk of a future clinical event. No
estimate is perfect, but a model that predicted the risk of
recurrent stroke just as well as or better than an expe-
rienced clinician might improve clinical practice. Some
prediction models are used widely in clinical practice
to quantify risk of future vascular events (for example, the
ASSIGN [2], Framingham [3], and CHADS [4] scores).tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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after stroke is in widespread use, either because their
statistical performance is too poor or because the models
are too hard to use.
We sought to pool measures of statistical performance
of existing models and investigate whether there were
aspects of study design or analysis that might be improved
in the development of new models. Therefore, we systemat-
ically reviewed the literature on the development and evalu-
ation of prediction models for recurrent vascular events
after ischemic stroke in order to assess: (1) the quality of
the cohorts and the statistical methods used in their devel-
opment; and (2) their external performance. We aimed to
compare clinical prediction models with clinicians’ informal
predictions in a new prospective cohort study.
Methods
The analysis protocol is available at [5]. We searched
Medline and EMBASE databases from 1980 to 19 April
2013 with an electronic search strategy using a search
term for ‘stroke’ and synonyms for ‘clinical prediction
models’ [see Additional file 1] [6,7]. We also searched
reference lists, personal files and Google Scholar [8]
for citations of relevant articles.
Inclusion criteria
Eligible articles developed and/or evaluated a multivariable
clinical prediction model for the risk of recurrent ischemic
stroke, myocardial infarction (MI) or all vaso-occlusive
arterial events in cohorts of adult patients with ischemic
stroke (or mixed cohorts of ischemic stroke and transient
ischemic attack (TIA). We excluded any studies using
cohorts that included hemorrhagic strokes. We made
no language restrictions.
Data extraction
One author (DDT) screened all titles and abstracts
identified by the electronic search against the inclusion
criteria prior to full text assessment. Two authors
(DDT and WNW) extracted data independently with a
detailed data extraction form developed and piloted by
three of the authors (DDT, GDM and WNW). We resolved
discrepancies by discussion. We adapted quality items
from similar systematic reviews [6,7,9-13] (Table 1) as
no recommended tool for the appraisal of quality of
prediction models currently exists. We distinguished two
types of articles: (1) development studies reporting the
construction of a prediction model, and (2) evaluation
studies (also known as validation studies) assessing model
performance in a cohort of new patients.
All measures of model performance were extracted
along with any associated measures of uncertainty
(for example, 95% confidence intervals (CI) or standard
error). Two commonly used measures of performance are:‘calibration’ and ‘discrimination’ [23]. Calibration summa-
rizes how well the observed events match the predicted
events by dividing the cohort into groups of predicted risk
(for example, quintiles or deciles) and comparing the mean
predicted risk with the observed frequency. Discrimination
summarizes how well a model separates patients with the
event in follow-up from those without. The c-statistic is
a commonly used rank order measure of discrimination
ranging from no better than chance (0.5) to perfect (1.0)
discrimination. For a given pair of patients, one with the
event of interest and one without, the c-statistic is inter-
preted as the probability that a greater predicted risk is
given to the patient with the event than the patient with-
out. In logistic regression the Area under the Receiver
Operating Characteristic Curve (AUROCC) is equivalent
to the c-statistic.
Meta-analysis
If three or more studies assessed a model’s performance
we performed a random-effects meta-analysis using the
DerSimonian and Laird method [24] (implemented with
the ‘metafor’ package [25] in R version 2.13.1). A random-
effects meta-analysis allows for differences in model
performance that may be explained by differing case
mix between studies (for example, older patients or more
severe baseline strokes and so on). We estimated the 95%
prediction interval (PI) associated with the individual
pooled estimates which differs somewhat from the CI
[26]. The CI summarizes the precision of a parameter
estimate whereas the PI provides a plausible range within
which an unknown estimate will be expected to lie in
95% of future samples. We assessed publication bias with
Contour-enhanced funnel plots [27]. The PRISMA check-
list for our review is available as an online supplement
[see Additional file 1].
Evaluation cohort
Evaluation in an external cohort is the most robust test
of model performance and generalizability. The Edinburgh
Stroke Study (ESS) was a prospective observational
study of stroke patients admitted to the Western General
Hospital in Edinburgh between April 2002 and May 2005
with a minimum follow-up of one year. Details on the
study’s design are available elsewhere [28]. Clinicians
were asked to use ‘gut-feeling’ to estimate the absolute
risk of a recurrent stroke or a vascular event (that is,
stroke, MI or vascular death) within one year in patients
seen as outpatients. We compared models we identi-
fied using measures of discrimination and calibration
to clinicians’ informal estimations.
Results
We screened 12,456 articles by title and abstract (PRISMA
diagram Figure 1), thirteen of which were eligible for
Table 1 Quality assessment of articles
Quality item Comment
Internal validity
Sample cohort Prospectively collected data are of greater quality than retrospectively collected data and are preferred for model
development [14].
Loss to follow up Loss to follow up is common. Investigators should state the number of patients lost (or else the completeness
of follow-up [15] which takes into account the duration of follow-up) along with reasons/explanations.
An arbitrary proportion thought adequate for analysis is 90% complete follow-up [7].
Predictive/outcome variables Predictors and outcomes/follow-up time should be explicitly defined: otherwise invalid predictions may be produced.
Missing values A transparent summary of missing data and the methods used to handle them should be provided. Complete-case
analysis should be avoided in favor of multiple imputation methods [16,17]. A general rule of thumb suggests that
imputation should be considered if the proportion of missingness exceeds 5% of the data [18].
Statistical validity
Model building strategy A priori clinical knowledge should be used to inform selection of risk factors. Data driven predictor selection
(for example, stepwise selection) should be avoided where possible [19,20].
Handling of continuous variables Arbitrary categorization should be avoided [21]. Defined cut-points must be based on clinical reasoning.
Sample size The sample size used in derivation (derivation sample) must be reported along with a sufficient description of
baseline characteristics. The number of patients with the outcome event in follow-up (effective sample size)
should be reported: 10 events per fitted parameter is often used as a minimum number [22].
Model evaluation
Evaluation Internal validation techniques (for example, bootstrap sampling or cross-validation) provide a minimum check of
overfitting and optimism. External evaluation in new data is the most rigorous assessment of model generalizability.
Description of external cohort A description of the baseline characteristics should be reported to enable a comparison of the validation cohort to
the development cohort.
Discrimination and calibration Discrimination metrics should be provided, for example, the area under the receiver operating characteristic curve
(AUROCC). Model calibration should be studied using a calibration plot with estimated slope and intercept provided.
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list checks and forward citation searches in Google
Scholar. We found twelve development studies [see
Additional file 1 and Figure 2] that developed a total of
31 models (a median of two per study, interquartile
range (IQR) one to three). We found eleven evaluation
studies that evaluated four models [see Additional file 1].
Only one relevant study written in a language other than
English was included [29].
Model development studies: cohort characteristics
Studies which collect data prospectively have a lower risk
of information and selection biases for both baseline data
and outcome events occurring during follow-up. Most
studies used prospectively collected data, although
four of twelve did not [30-33], one of which [33] used
prospective trial data but included retrospective events
obtained beyond the trial’s original follow-up period. Few
(four of twelve) development studies recruited patients
consecutively from routine practice [30,31,34,35]. Loss of
patients to follow-up often occurs when studies last for
long time periods. Most (nine of twelve) [30-33,35-39]
development studies reported loss to follow up; where
this could be calculated (seven of eight) [31-33,35-39]
rates of loss were small (less than 5%).
The most frequent variables included in multivariable
clinical prediction models were: age, history of TIA orstroke, history of hypertension, and diabetes [see Additional
file 1]. Five articles [31,32,34,36,39] defined all predictors,
three [30,35,37] defined only some, and four [33,38,40,41]
did not define any. Most articles defined outcome ad-
equately, although three did not define the outcome
and/or the duration of follow-up [38,40,41].
Missing baseline data occur frequently when collecting
information from patients. A complete case analysis using
only those patients with complete baseline data risks selec-
tion bias and loss of information. Five of the development
studies [32-34,38,41] reported missing data, four [32-34,38]
of which stated the impact a complete case analysis had
on the derivation sample size. No attempts were made to
impute missing data.
Model development studies: statistical methods
Most investigators collect more potential predictors than
are included in a final model. Data dependent methods
(for example, univariate selection or stepwise selection)
are often used to select a few important variables from
those available to develop a prediction model. This can
lead to over-fitted models that perform over-optimistically
in their development datasets which may be impossible to
replicate in external evaluation [42]. Most of the studies
used data dependent variable selection methods: stepwise
selection (two of twelve) [32,35]; univariate significance
tests (four of twelve) [30,31,34,36]; and further reduction
23 articles eligible for review
10 articles included after 
reference check and forward 
citation 
13 articles eligible for review
59 of full-text articles 
Reasons for exclusion:
Risk factor study (25)
Endpoint not appropriate (7)
Primary aim not model 
development (11)
Other (16)
72 full-text articles assessed 
for eligibility
12,384 excluded on abstract
12,456 articles after duplicates were removed
11,074 articles identified through 
electronic search (EMBASE)
6,985 articles identified through 
electronic search (Medline)
Figure 1 PRISMA flow diagram of selected studies.
Thompson et al. BMC Medicine 2014, 12:58 Page 4 of 9
http://www.biomedcentral.com/1741-7015/12/58of univariate selection by inspection of multivariable
significance (two of twelve) [33,38]. Three modifications
of pre-existing prediction models were identified with
new predictors chosen by clinical justification [37,39,41].
One study gave no description of how variables were
selected [40].
Internal evaluation methods can use the model devel-
opment data to provide optimism-corrected estimates of
model performance. Few authors internally assessed the
performance of their models (three of twelve) using such
cross-validation methods [30,31,37].
Models were derived using Cox proportional hazard
regression (nine of twelve) [30,32-36,38,39,41] or multivari-
able binary logistic regression (three of twelve) [31,37,40].
Most studies presented their models as point scores
(seven of twelve) by rounding regression coefficients
[30-32,34,37,40,41]. The categorization of a continuous
predictor results in the loss of information. The majority ofstudies categorized continuous predictors (eight of twelve)
[30-32,34,36,37,40,41], only one of which gave some clinical
justification for the cut-points chosen [37]. The remaining
four studies used a mixture of categorized and continuous
variables [33,35,38,39].
A common rule of thumb used in prediction model
literature is the ‘ten events per tested variable’ (10 EPV)
rule. The median total sample size across the twelve devel-
opment studies was 1,132 (IQR 522 to 3,123). Where re-
ported (nine of twelve), the median number of events was
73 (IQR 60 to 102). Only one of the five studies where
the EPV could be calculated had more than the minimum
recommended EPV [37].
Model evaluation studies: study characteristics
The ESSEN Stroke Risk Score (ESRS) [40], the Stroke
Prognosis Instrument II (SPI-II) [41], the Recurrence
Risk Estimator at 90 days (RRE-90) [30] and the Life Long
0 25 50 75 100
Percentage meeting quality criterion
1 / 5
4 / 12
3 / 12
5 / 12
9 / 12
5 / 12
7 / 8
8 / 12
Continuous predictors not categorised
Pre−defined predictors
Reported missing data
Defined outcome
Defined all predictors
Loss to follow up <5%
Prospective data collection
Events per variable ≥ 10
n / NQuality criterion
Figure 2 Aspects of model development.
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ated in eleven different studies [see Additional file 1]. We
identified four additional evaluations among the model
development studies [30,37,39,41] giving fifteen evaluation
cohorts: five evaluations of the ESRS [29,37,43-45]; three of
the SPI-II [41,46,47]; five head-to-head comparisons of the
ESRS and the SPI-II [30,39,48-51]; one head-to-head com-
parison of the ESRS and the RRE-90 [52]; and one compar-
ing the ESRS, the SPI-II and the LiLAC models [50].
The median sample size in the 15 evaluation cohorts
was 1,286 (IQR 619 to 5,004). Various combinations of
events and follow-up periods were used yielding 49 specific
AUROCC values for extraction [see Additional file 1].
Where the effective sample size could be determined
the median size was 86 (IQR 58 to 134).
Model evaluation studies: statistical performance
The pooled AUROCC value for the ESRS was 0.60
(95% CI 0.59 to 0.62) and for the SPI-II was 0.62 (95%
CI 0.60 to 0.64) (Figure 3). Six head-to-head comparisons
of the ESRS and the SPI-II were identified. Four of these
[39,49-51] (the other two [30,48] used much shorter
follow-up periods) were pooled to calculate the AUROCC
estimates: 0.61 (95% CI 0.58 to 0.64) with 95% PI (0.29
to 0.93) and 0.62 (95% CI 0.59 to 0.66) with 95% PI
(0.23 to 0.99), respectively, for the ESRS and the SPI-IIscores. These findings were robust to sensitivity analyses
[see Additional file 1]. One evaluation study for the RRE-90
score estimated an AUROCC of 0.72 (95% CI 0.64 to 0.80)
[52] and another of the LiLAC score estimated an
AUROCC of 0.65 (95% CI 0.61 to 0.70) [50]. We identified
two evaluations of the ABCD2 score [48,52,53]. Although
the ABCD2 score was developed and designed for patients
withTIA (and, therefore, did not meet our inclusion criteria)
its performance was similar to other clinical prediction
models for recurrent stroke (Figure 3). Only one study
assessed the calibration of the SPI-II score which found
it to be good but only after re-calibration [47]. There
was no evidence for small study (that is, publication) bias
[see Additional file 1].
Model evaluation: comparative performance with
clinical gestalt
Baseline characteristics for the ESS can be found online
[see Additional file 1].We were able to evaluate five of
twelve models in the ESS (Table 2). In the ESS data, 575
patients had informal predictions for vascular outcomes
by one year. We were able to obtain information regard-
ing thirteen of the clinicians making predictions for 542
(94%) of the patients. Of these: eight were neurologists
(62%) and five were stroke physicians (38%); seven were
in training (54%) and six were fully trained (46%). The
Table 2 Performance of models in the Edinburgh Stroke Study
Recurrent stroke (50/671)a Any vascular event (80/671)a Original development outcomeb
Model n/N AUROCC 95% CI n/N AUROCC 95% CI n/N AUROCC 95% CI
Clinical gestalt 40/575 0.53 0.44 to 0.63 63/574 0.56 0.48 to 0.64 - - -
ESRS 50/664 0.56 0.48 to 0.64 80/664 0.57 0.50 to 0.63 101/1,224 0.54 0.49 to 0.60
SPI-II 50/669 0.58 0.49 to 0.66 80/669 0.59 0.52 to 0.66 274/1,253 0.63 0.59 to 0.67
RRE-90c 50/671 0.61 0.52 to 0.69 80/671 0.59 0.53 to 0.66 52/1,254 0.59 0.51 to 0.67
Putaala 50/669 0.48 0.39 to 0.57 80/669 0.56 0.49 to 0.63 269/1,247 0.65 0.61 to 0.68
Dhamoon 50/668 0.60 0.52 to 0.68 80/668 0.61 0.54 to 0.67 205/1,253 0.73 0.69 to 0.76
Cell entries are AUROCCs for a recurrent stroke by one year, all vascular events by one year, and the outcome as defined in development. Few patients were deleted due to
missingness for prediction models (671 outpatients with 50 strokes in follow-up and 80 vascular events; and for all patients 1,257, 102 and 274 respectively). aOutpatients
only; bone year follow-up was available for all patients in the ESS; cModel A was the clinical based model. AUROCC, area under the receiver operating characteristic curve; CI,
confidence interval; ESRS, ESSEN Stroke Risk Score; RRE-90, Recurrence Risk Estimator at 90 days; SPI-II, Stroke Prognosis Instrument II.
0.00 0.25 0.50 0.60 0.70 0.80 0.90 1.00
AUROCC
Ay (2010)
Chandretheva (2011)
Weimar (2010)
Weimar (2008)
Weimar (2009)
Weimar (2012)
Maier (2013)
Meng (2011)
Stahrenberg (2013)
Sumi (2012)
ESS
Ay (2010)
Chandretheva (2011)
Kernan (2000)
Navi (2011)
Weimar (2010)
Weimar (2012)
Wijnhound (2010)
Meng (2011)
Stahrenberg (2013)
ESS
Chandretheva (2011)
Maier (2013)
Maier (2013)
ESS
Maier (2013)
Weimar (2010)
0.59 [ 0.53 , 0.65 ]
0.50 [ 0.42 , 0.58 ]
0.65 [ 0.61 , 0.69 ]
0.61 [ 0.54 , 0.68 ]
0.60 [ 0.58 , 0.62 ]
0.59 [ 0.56 , 0.62 ]
0.59 [ 0.50 , 0.68 ]
0.60 [ 0.59 , 0.61 ]
0.70 [ 0.57 , 0.82 ]
0.61 [ 0.56 , 0.66 ]
0.62 [ 0.59 , 0.66 ]
0.56 [ 0.49 , 0.63 ]
0.48 [ 0.38 , 0.58 ]
0.63 [ 0.62 , 0.64 ]
0.62 [ 0.61 , 0.63 ]
0.66 [ 0.62 , 0.70 ]
0.60 [ 0.57 , 0.63 ]
0.68 [ 0.61 , 0.75 ]
0.60 [ 0.59 , 0.61 ]
0.70 [ 0.59 , 0.81 ]
0.63 [ 0.59 , 0.67 ]
0.62 [ 0.54 , 0.70 ]
0.60 [ 0.52 , 0.68 ]
0.72 [ 0.56 , 0.88 ]
0.59 [ 0.51 , 0.67 ]
0.75 [ 0.66 , 0.84 ]
0.65 [ 0.61 , 0.69 ]
Author(s) and Year
ESRS
SPI−II
ABCD2
RRE−90 (Model A)
RRE−90 (Model B)
LiLAC
Weight % AUROCC [95% CI]n/N
Pooled studies
Single studies
0.60 [ 0.59 , 0.62 ]Subtotal (I−squared = 30.63%, p = 0.1548)
with estimated predictive interval [ 0.57 , 0.63 ]100.0 %
10.11 %
6.59 %
1.12 %
31.31 %
2.18 %
10.89 %
20.88 %
3.07 %
7.44 %
2.43 %
3.98 %
256/1224
133/3292
23/197
NA/11384
95/1727
NA/846
NA/15605
60/700
135/1897
49/520
NA
0.62 [ 0.60 , 0.64 ]Subtotal (I−squared = 66.52%, p = 0.0015)
with estimated predictive interval [ 0.57 , 0.67 ]100.0 %
11.16 %
2.22 %
18.21 %
4.85 %
11.46 %
8.84 %
18.21 %
18.21 %
2.47 %
4.35 %
274/1253
23/197
NA/11384
57/592
NA/846
135/1897
1422/5575
1241/9220
49/514
NA
95/1727
49/520
52/1254
95/1727
95/1727
135/1897
Figure 3 Meta-analysis of AUROCC values for ESRS and SPI-II (percentage weights are from random effects analysis). N = sample size,
n = number of events in follow-up, and NA missing information. AUROCC, area under the receiver operating characteristic curve; ESRS, ESSEN
Stroke Risk Score; SPI-II, Stroke Prognosis Instrument II.
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(ranging from 1 to 217). For recurrent stroke within one
year clinicians discriminated poorly between those
who did and those who did not suffer an event with an
AUROCC of 0.54 (95%CI 0.44 to 0.62). Formal predic-
tion also discriminated poorly with AUROCC measures
varying between 0.48 and 0.61. For risk of vascular
events, clinicians again discriminated poorly with an
AUROCC of 0.56 (95%CI 0.48 to 0.64) and formal pre-
diction ranged from 0.56 to 0.61. The AUROCCs from
the ESRS and the SPI-II were calculated for all pa-
tients in the ESS for any vascular event and added to
the meta-analysis.
Discussion
We found four externally evaluated clinical prediction
models for the prediction of recurrent stroke and MI
after stroke: the ESRS, the SPI-II, the RRE-90 and LiLAC.
The discriminative performances of the models were
similar to one another, but only modest at best, with
AUROCC values ranging from 0.60 to 0.72. The perform-
ance of some of the clinical prediction models although
modest was similar to experienced clinicians.
There were some weaknesses in the methodology of
model development which may explain the modest
performance observed in external evaluation studies of
clinical prediction models. First, continuous variables
were often categorized which leads to a loss of predictive
information. Second, data-dependent variable selection may
have led to over-fitting of models to the observed data.
Third, cohorts were generally too small for reliable model
development: we found only one study with more than the
recommended 10 EPV. Small samples can lead to predic-
tion models that are over-fit on the available data which is
further compounded by implementing a complete case
analysis. Fourth, the cohorts used to develop the models
had weaknesses that are frequent in epidemiological
studies: there were missing baseline data; whether the
recruited patients were representative of those seen in
routine clinical practice was uncertain; some data were
collected retrospectively; and most cohorts did not record
all potentially predictive variables. For example, the pres-
ence of multiple infarcts on MR scanning was only consid-
ered in one model [30,54].
While it seems more likely that a well-developed model
will have better performance in external evaluation,
the only reliable method for choosing between models
is their performance in evaluation studies of represen-
tative patients. Despite the differences in the methods
of derivation of the ESRS, the SPI-II and the LiLAC,
they discriminated similarly (and modestly) between
patients with and without recurrent stroke [50]. The
ESRS and the SPI-II have four predictors in common
(age, history of TIA or stroke, diabetes and blood pressure).Three head-to-head comparisons demonstrated a relative
difference in AUROCC which did not exceed 2% [49-51].
This is one of the few studies of the performance of
clinicians’ predicting vascular events. Although such
investigations perhaps provide the most robust argument
for or against the use of statistical prediction, they remain
rare. For example, there are many prediction rules for
poor outcome or disability after stroke [55] but few have
been tested against clinicians’ informal predictions [56].
Implications for research
Although discrimination of recurrent events by clinical
prediction models was poor, our study indicates that it
may be similar to informal clinicians’ prediction. In
addition, we identified a number of areas that could
improve the discrimination of clinical prediction models
for recurrent stroke or MI that future model developers
could consider: (1) using all the available information from
a cohort by avoiding the categorization of continuous
predictors and using multiple imputation of missing data
where a complete case analysis would exclude a significant
proportion of the cohort; (2) reporting regression coef-
ficients (that is, prior to any transformation) to allow
more accurate evaluation of models in independent co-
horts. Point score models are probably obsolete as more
precise predictions can easily be obtained using applications
accessed via mobile computers at the bedside. There are
too many proposed models in clinical practice to remem-
ber them all, and it is only sensible that they should be
available electronically; and finally, (3) measuring whether
newly identified predictors (for example, blood markers
or imaging techniques) add to the accurate classification
of patients over more easily measured variables, for ex-
ample using the net reclassification index [39,57].
A number of methodological decisions in model develop-
ment may lead to clinical prediction models that make less
accurate predictions [58] and we believe that an agreed set
of guidelines in model development and reporting in
healthcare would be helpful to developers and users of
clinical prediction models alike [59].
Limitations of the study
Assessing the quality of studies of predictive models is
difficult, and there is no widely agreed set of guidelines.
This is likely to become an increasing problem as such
studies are frequent and very likely will begin to influence
practice. Our electronic search was overly sensitive and
returned a small number of relevant articles; hence, we did
not perform additional searches of the ‘grey’ literature. This
is an unfortunate artefact of poor indexing, as there is no
Medical Subject Heading (MESH) term for clinical predic-
tion models. We attempted to work around these limita-
tions with forward citation searching in Google Scholar.
The ESS did not classify stroke according to the Causative
Thompson et al. BMC Medicine 2014, 12:58 Page 8 of 9
http://www.biomedcentral.com/1741-7015/12/58Classification of Stroke System (CCS); we instead manipu-
lated a record of classification as per the Trial of Org 10172
in Acute Stroke Treatment (TOAST) algorithm to a format
that closely resembled the CCS.
Conclusions
We found that the available clinical prediction models
for recurrent stroke and MI after stroke discriminated
modestly between patients who do and do not have re-
current events. Clinicians’ informal predictions discrim-
inated similarly to the models. Aspect of study design
and statistical methodology were poor amongst model
development studies, however, and performance might
be improved with better methods.
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